The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net income (loss) | 4,337,820 | 4,330,608 | -143,558 |
| Payment of operating costs through promissory note | - | -1 | 77,800 |
| Interest earned on cash and investments held in trust account | 4,439,850 | 4,824,445 | 109,355 |
| Gain on extinguishment of over-allotment option liability | - | 553,748 | - |
| Provision for credit losses | - | 812,113 | - |
| Recovery of credit losses | -30,000 | - | - |
| Prepaid expenses | -21,773 | 10,814 | -27,580 |
| Due from sponsor | -30,000 | 245,844 | 566,269 |
| Accounts payable and accrued expenses | -22,246 | 94,767 | 4,592 |
| Accrued expenses | - | 82,500 | 5,843 |
| Net cash used in operating activities | -102,503 | -314,864 | -703,367 |
| Investment of cash into trust account | - | 0 | 500,000,000 |
| Net cash used in investing activities | - | 0 | -500,000,000 |
| Proceeds from sale of units, net of underwriting discounts paid | - | 0 | 490,000,000 |
| Proceeds from sale of private placement units | - | 0 | 12,000,000 |
| Repayment of promissory note - related party | - | 0 | 533,781 |
| Payment of offering costs | - | 0 | 464,800 |
| Proceeds from promissory notes | 450,000 | - | - |
| Net cash provided by financing activities | 450,000 | 0 | 501,001,419 |
| Net change in cash | 347,497 | -314,864 | 298,052 |
| Cash beginning of period | 223 | 315,087 | 17,035 |
| Cash end of period | 347,720 | 223 | 315,087 |
Drugs Made In America Acquisition II Corp. (DMIIU)
Drugs Made In America Acquisition II Corp. (DMIIU)